The United Kingdom's drug regulator said AstraZeneca’s Covid-19 vaccine has huge benefits but people under 30 will be offered another product due to a rare blood clot risk.
The Medicines and Healthcare Products Regulatory Agency (MHRA) said Wednesday that while it is studying the possible connection between AstraZeneca's coronavirus vaccine and rare blood clots, the Pfizer and Moderna vaccines should be offered to people in that age group.
Dr June Raine, the head of the MHRA, says that the benefits “continue to outweigh the risks for the vast majority of people.”
The decision was announced soon after the European Union's drug regulator said it had found a “possible link” between the AstraZeneca coronavirus vaccine and a rare clotting disorder. But that agency did not recommend any new restrictions on the vaccine for people 18 and over, saying the benefits of the shot still outweigh risks.
For in-depth, objective and more importantly balanced journalism, Click here to subscribe to Outlook Magazine